Corline Biomedical
10,3 SEK +0,98%Vær den første som følger denne virksomhed
Corline Biomedical operates in the pharmaceutical industry. The company develops with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The drug candidates are based on the same basic technology as the medical technology products. Corline Biomedical operates on the Nordic market and is headquartered in Uppsala.
Omsætning
25,03 mio.
EBIT %
-7,15 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
CLBIO
Daglig lav / høj pris
10 / 10,35
SEK
Markedsværdi
221,36 mio. SEK
Aktieomsætning
10,14 t SEK
Volumen
989
Finanskalender
Delårsrapport
30.04.2024
Generalforsamling
15.05.2024
Delårsrapport
23.08.2024
Delårsrapport
07.11.2024
Årsrapport
17.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Adam Dahlberg | 26,7 % | 26,7 % |
HealthInvest Microcap Fund AB | 9,9 % | 9,9 % |
Premium
This content is for our Premium customers only.